Observational Study on the Safety and Effectiveness of Finerenone in Adults with Chronic Heart Failure and LVEF 40% in South Korea

What this Trial Is About

Researchers are observing people in South Korea who have chronic heart failure with a left ventricular ejection fraction LVEF of 40% or higher and are receiving finerenone. The study aims to understand the safety and effectiveness of finerenone, a medicine that targets a receptor in the body to reduce harm to the heart, kidneys, and blood vessels. This medication is already approved and prescribed by doctors, and the study focuses on gathering data from everyday medical care without changing treatments. Participants will receive finerenone as prescribed by their doctors during their regular medical visits. The study collects data from those who are starting finerenone treatment for chronic heart failure with LVEF of 40% or greater. There are no additional tests or visits required for the study information is gathered from medical records and interviews during routine care. During the one-year period after joining the study or until participants decide to leave, researchers will monitor any side effects or health issues that may be related to finerenone. They will also track how satisfied doctors are with the treatment over time, including symptom improvement, quality of life, and overall health. Changes in finerenone dosing will be recorded as part of the evaluation of how well the medicine works.

A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea